Antimicrobial Photodynamic Therapy With New Methylene Blue and Its Combined Effect With Antibiotics Against MDR Acinetobacter baumannii. (2026)

Peer-Reviewed Study · Barati B, Navidifar T, Ostovari M, Ghanavati R, Darbandi A · June 2026

Barati B et al., 2026-06: Iranian 2026 laboratory study of new methylene blue-mediated antimicrobial photodynamic therapy combined with tigecycline and colistin against multidrug-resistant Acinetobacter baumannii, reporting 1.7-2.6 log10 reductions at sublethal dye doses.

The present study aimed to evaluate the antibacterial efficacy of new methylene blue-mediated antimicrobial photodynamic therapy

e70342

Barati B et al., 2026-06: Iranian 2026 laboratory study of new methylene blue-mediated antimicrobial photodynamic therapy combined with tigecycline and colistin against multidrug-resistant Acinetobacter baumannii, reporting 1.7-2.6 log10 reductions at sublethal dye doses. C8 Iran. Study type: in-vitro microbiology (MIC, checkerboard, ROS assays); no patients. Doses: new methylene blue 12.5 (sublethal), 25 and 50 microg/mL with irradiation; radiation times varied. Comparator: untreated control and antibiotic monotherapies. Funder/conflicts: authors declare no conflicts of interest. Journal Microbiologyopen 15(3):e70342. Bearing PARTLY: laboratory only, and the agent is new methylene blue, a different dye from methylene blue (methylthioninium chloride). Also filed as MTL-096 (claims C8, C9). Study type: lab.